VYNE – vyne therapeutics inc. (US:NASDAQ)

News

VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor [Yahoo! Finance]
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
VYNE Therapeutics Inc. (NASDAQ: VYNE) is now covered by analysts at BTIG Research. They set a "buy" rating and a $8.00 price target on the stock.
VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com